Advertisement

Understanding Hormone Receptors and HER2 Receptor

  • Radhakrishna Selvi
Chapter

Abstract

Breast cancer is a heterogeneous disease with a varied clinical outcome, underscoring the need for the use of reliable predictive and prognostic biomarkers. Prognostic markers help in estimating clinical outcome while predictive markers are required for optimal therapeutic decision making. Testing for steroid hormone receptors and HER2 oncogene have been, for many years, the mainstay of breast cancer management, both for prognostication and in predicting response to hormonal therapy, anti-HER2 therapy, and chemotherapy. Ki67, a key proliferative marker, has in recent times, evoked much interest due to its moderate prognostic value and its role in neoadjuvant therapy. Recent molecular advances have also identified several other single gene products as well as, more critically, multigene signatures for breast cancer which can provide further prognostic and predictive information, to help fine-tune treatment strategies.

Keywords

Breast Cancer Progesterone Receptor HER2 Gene HER2 Gene Amplification Estrogen Receptor Positive Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Reading

  1. 1.
    Elizabeth M, Hammond H et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med. 2010;134.Google Scholar
  2. 2.
    Fitzgibbons PL, Murphy DA et al. Recommendations for Validating Estrogen and Progesterone Receptor Immunohistochemistry Assays. Arch Pathol Lab Med. 2010;134.Google Scholar
  3. 3.
    Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathology. 2008;21:S8–S15.Google Scholar
  4. 4.
    Sauter G, Lee J, Bartlett JMS, Slamon DJ, Michael F. Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. J Clin Oncol. 2009;27:8.Google Scholar
  5. 5.
    Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol. 2008;61:689–696.Google Scholar
  6. 6.
    Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocrine-Related Cancer 2010;17:R245–R262.Google Scholar
  7. 7.
    Wolff AC, Elizabeth M, Hammond H. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2007;131.Google Scholar
  8. 8.
    Wolff AC, Elizabeth M, Hammond H. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013;31.Google Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  • Radhakrishna Selvi
    • 1
  1. 1.Chennai Breast CentreChennaiIndia

Personalised recommendations